Reckitt’s 2025 performance was seen as the minimum expectation rather than a trigger—attention now shifts to the outlook for 2026

Reckitt’s 2025 Performance: Strong Results, Cautious Outlook

Reckitt posted impressive numbers for fiscal 2025, with core like-for-like net revenue rising by 5.2%, surpassing its own medium-term growth target of 4-5%. The company also saw a remarkable 83% increase in pre-tax profit, reaching GBP 3.84 billion, and reported an adjusted earnings per share of 352.8 pence, a slight 1.1% improvement from the previous year. On paper, these results exceeded expectations across the board.

However, the market’s response was less enthusiastic. Following the announcement, Reckitt’s shares dropped by 2.3% to 5,910 pence. This reaction reflects a classic “sell the news” scenario, where the positive results were already anticipated and factored into the share price. The 5.2% revenue growth had likely been expected, and with no new surprises, investors saw little reason to push the stock higher.

Attention has now shifted to the company’s future prospects. Management reiterated its 2026 guidance of 4-5% core revenue growth, but the tone was notably cautious. The company highlighted a softer cold and flu season and ongoing difficulties in the European market for the first quarter, signaling near-term challenges. As a result, the strong 2025 performance is now seen as the new baseline, and investors are looking for evidence that the 2026 targets can be met despite these obstacles.

The Expectation Gap: Growth Momentum Meets Cautious Guidance

There is a clear disconnect between Reckitt’s robust 2025 results and its more reserved outlook for the future. By reaffirming its 2026 revenue growth target of 4–5%, management has effectively set last year’s 5.2% as the new standard rather than a stretch goal. The market is now adjusting its expectations, making this guidance the key reference point for the year ahead.

RSI(14) Oversold Long-Only Strategy Backtest

• Strategy: Enter a long position in RBGLY when RSI(14) falls below 30. Exit when RSI(14) rises above 70, after 20 trading days, or if a take-profit (+8%) or stop-loss (−4%) is triggered. Backtest period: March 6, 2024, to March 5, 2026.

Trade Signals

• Entry Condition: RSI(14) < 30
• Exit Conditions: RSI(14) > 70, 20-day hold, take-profit at +8%, or stop-loss at −4%
• Asset: RBGLY
• Risk Controls: Take-profit: 8%, Stop-loss: 4%, Maximum hold: 20 days

Backtest Results

• Total Return: 27.03%
• Annualized Return: 18.86%
• Maximum Drawdown: 43.45%
• Profit-Loss Ratio: 0.84

Trade Statistics

• Total Trades: 15
• Winning Trades: 9
• Losing Trades: 6
• Win Rate: 60%
• Average Holding Period: 8.93 days
• Maximum Consecutive Losses: 2
• Average Gain per Win: 10.78%
• Average Loss per Loss: 10.29%
• Largest Single Gain: 24.52%
• Largest Single Loss: 26.04%

Regional Challenges and Growth Disparities

Reckitt faces two immediate hurdles. First, a milder cold and flu season is expected to weigh on the over-the-counter segment in the first quarter. Second, the European market continues to pose difficulties, a trend that persisted throughout 2025. This regional split is at the heart of the expectation gap: while European sales dropped by 4.5% in the final quarter, Emerging Markets surged by 17.2%. This contrast highlights the uneven pace of recovery and the pressure on the company’s growth drivers.

In essence, the 2025 outperformance was fueled by strength in emerging markets and improved margins. Looking ahead, the focus shifts to navigating ongoing European weakness. The market has already absorbed last year’s positive news and is now watching to see if management can achieve the 4-5% growth target amid these challenges. The revised guidance is now the benchmark for expectations.

Financial Discipline and Capital Deployment

Reckitt’s 2025 success was not limited to revenue growth. The company demonstrated strong financial management, with its adjusted operating margin for Core Reckitt increasing by 90 basis points to 26.7%. This improvement reflects the effectiveness of the Fuel for Growth cost-saving initiative, which has strengthened profitability. Robust free cash flow of £1.7 billion enabled Reckitt to return £2.3 billion to shareholders through buybacks and a special dividend, underscoring management’s confidence in the company’s cash-generating ability. The year ended with a healthy net debt to EBITDA ratio of approximately 1.6x, providing financial flexibility.

Looking forward, the board anticipates leverage rising to around 2.5x by mid-2026, due to ongoing investments and a lower EBITDA base following the sale of Essential Home. This increase in leverage is a direct outcome of the company’s capital allocation choices—balancing growth investments with shareholder returns. While the quality of earnings remains high, investors must now consider the implications of higher leverage alongside growth prospects.

Key Drivers and Risks for 2026

With the 2025 results now history, Reckitt’s valuation depends on its ability to deliver on a more moderate growth path in 2026. The main catalyst will be achieving the 4–5% core revenue growth goal while overcoming two significant headwinds: stabilizing the European market and managing a softer over-the-counter category. Any misstep could widen the gap between expectations and reality, putting pressure on the stock.

Success will depend on two main factors. First, continued progress with the Fuel for Growth program, which aims to support supply chain expansion and innovation while offsetting the impact of the Essential Home divestment. Second, the market will be watching for the impact of new product launches, such as the upcoming Mucinex 12-hour, to drive growth in key segments. These initiatives will determine whether the 4-5% target is achievable or overly ambitious.

The biggest risk is that the gap between last year’s 5.2% growth and the 2026 target widens further. The sharp contrast between Emerging Markets’ 17.2% growth and Europe’s 4.5% decline in 2025 highlights the company’s vulnerabilities. If European weakness continues and the over-the-counter segment remains sluggish, Reckitt may find it difficult to meet its own guidance. In that case, the stock could face renewed selling pressure as investors weigh the trade-off between increasing leverage and slower growth. For now, the market is expecting steady progress, but the next few quarters will reveal whether those expectations are realistic.